Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
about
Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT studyThe number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.Imaging of normal and pathologic joint synovium using nonlinear optical microscopy as a potential diagnostic tool.Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review.Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegolTreatment of rheumatoid arthritis.Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended studyGene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritisConsensus statement on the use of rituximab in patients with rheumatoid arthritisClinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.Placenta suppresses experimental autoimmune hypophysitis through soluble TNF receptor 1Prefilled certolizumab pegol (Cimzia(®)) syringes for self-use in the treatment of rheumatoid arthritisPharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies.Is the damage of cartilage a global or localized phenomenon in hip dysplasia, measured by dGEMRIC?Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesCytokines and the early vein graft: strategies to enhance durability.Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States.Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.Mechanical injury and cytokines cause loss of cartilage integrity and upregulate proteins associated with catabolism, immunity, inflammation, and repairMany cytokines are very useful therapeutic targets in disease.Evidence that cytokines play a role in rheumatoid arthritis.The CDK domain of p21 is a suppressor of IL-1beta-mediated inflammation in activated macrophages.A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.Abatacept for the treatment of rheumatoid arthritis: A review.Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.What can the periodontal community learn from the pathophysiology of rheumatoid arthritis?TNF-α signaling in Fanconi anemia.Temporal cytokine expression and the target organ attributes unravel novel aspects of autoimmune arthritis.Biologic therapy for refractory scleritis: a new treatment perspective.Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.Tumour necrosis factor inhibitors and infection: What is there to know for infectious diseases physicians?Are biologics more effective than classical disease-modifying antirheumatic drugs?TNF-alpha and shear stress-induced large artery adaptations.Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis.Re-challenge with etanercept in patients with etanercept-induced neutropenia.'Like the worst toothache you've had' - How people with rheumatoid arthritis describe and manage pain.Change of psychological distress and physical disability in patients with rheumatoid arthritis over the last two decades.β-Endorphin attenuates collagen-induced arthritis partially by inhibiting peripheral pro-inflammatory mediators.
P2860
Q24674942-0AC02341-C25F-481D-B309-97D264A37E49Q33311301-0C33684D-7BC0-43F1-8819-CE57BA4E145AQ33739631-E575A958-A634-46E1-904F-3CC1FE26B77EQ33939033-6868F005-D49C-479E-9E54-575D2334C04EQ34117111-5B0F5713-002B-41A7-91C4-2152C04A19E9Q34276242-B1BBFF36-1915-4FC6-A279-404ACA7C26E9Q34562870-37C0E022-7CEF-4951-B165-009F87064BA2Q35605604-C1F4CCE8-9A25-41C3-B2B8-1A7BCF8A0B0BQ35638676-68FF1729-97C3-4C1A-9EFF-CDA7E49AF1C3Q35954497-498DAD6A-EDD3-4285-92AC-447CA8392A15Q36020169-80B2EA12-B01C-4BFC-A940-4FFBAE82B1D0Q36160421-889FF280-0C91-473D-993E-8A360FB8F443Q36441438-1C5BCAA9-9258-47EA-96B0-3BD420B3F9FDQ36484821-570FBCA9-8535-4414-B2F2-4A59543953E1Q36724093-AF965169-0113-44EE-8BD0-036EF70FDF87Q36837890-AC9DD297-3307-43EA-ADAA-D8D6DF717487Q36893038-5D9EF18D-5B5A-4F7B-95CA-62C766ABF241Q37172820-99B74F42-CE07-48D1-8F53-1C9A4EC935EEQ37258065-543B0BAA-CA98-469B-A4B2-CD056BD28441Q37316591-26C16C1D-1E9A-4872-900D-FF90356BFAFAQ37316594-A9D47B0E-BDBD-4F85-9968-B808747378ADQ37324160-981D9D9A-3A22-4E01-B52B-DB2BD505A1D8Q37561560-7EDA0084-2E46-44EA-87E7-33C6F8289E53Q37672814-314E3019-A5F7-43DA-A335-1D65F05C4373Q37782588-F7C2F775-3C46-46A3-A834-37C10262F655Q37842638-EFCADFF1-30DD-4773-8F05-A31F3EEDF0B9Q38124483-D0172F0F-DE5F-462F-8921-F3D288A31BC1Q38179171-C6581CF7-9B36-4E31-A727-8F95F7B3A10CQ38576234-29FF262C-0AEE-4149-A31D-4F55303F54FDQ40081220-592766EE-35FC-498E-90A5-85BAC88C857BQ40672157-8E8D3DE9-61EA-4148-B1AE-9C957E12DE0EQ41396342-6CD6F1DD-2121-4047-9734-2837393470A8Q42588233-3D526073-039B-4CAB-9EFE-17A34FBA06FFQ42955185-06AF0259-528F-4FE3-888E-90E5D1097C8BQ44586802-042A5F07-F620-4105-92EC-F1D8A88AB93CQ47346117-46346AEA-E283-4C1E-9DFC-ED8CBD148DDAQ51180314-78C436CC-EF59-436A-8F16-5A2CE393737AQ55180989-8B3825A6-B2B0-4BD1-AF90-3B1309E8D46F
P2860
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Updated consensus statement on ...... nt of rheumatic diseases, 2005
@ast
Updated consensus statement on ...... nt of rheumatic diseases, 2005
@en
Updated consensus statement on ...... nt of rheumatic diseases, 2005
@en-gb
type
label
Updated consensus statement on ...... nt of rheumatic diseases, 2005
@ast
Updated consensus statement on ...... nt of rheumatic diseases, 2005
@en
Updated consensus statement on ...... nt of rheumatic diseases, 2005
@en-gb
prefLabel
Updated consensus statement on ...... nt of rheumatic diseases, 2005
@ast
Updated consensus statement on ...... nt of rheumatic diseases, 2005
@en
Updated consensus statement on ...... nt of rheumatic diseases, 2005
@en-gb
P2093
P2860
P50
P356
P1476
Updated consensus statement on ...... nt of rheumatic diseases, 2005
@en
P2093
Bijlsma JW
Breedveld FC
Dougados M
Keystone EC
P2860
P304
P356
10.1136/ARD.2005.044941
P407
P478
64 Suppl 4
P577
2005-11-01T00:00:00Z